Filing Flows

Filing Flows › 8-K events › Biocryst Pharmaceuticals

Biocryst Pharmaceuticals: results of operations

Form 8-K filed Nov 4, 2026 · items 2.02, 7.01

Results of operationsBioCryst Reports Third Quarter 2026 Financial Results

What the filing says

BioCryst Reports Third Quarter 2026 Financial Results — Total net revenue of $180.3 million and ORLADEYO ® net revenue of $174.8 million —

ScaleThe filing names $180.3M: about 25% of Biocryst Pharmaceuticals' annual revenue ($721.2M, four times the latest quarter).

Read the filing on SEC EDGAR →

What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Every item ranked →

Biocryst Pharmaceuticals at a glance

Latest quarterQ3 2026
Revenue$180.3M
Revenue Y/Y+13%
Operating margin29.6%
IndustryBiological Products, (No Diagnostic Substances)

Biocryst Pharmaceuticals, Q3 2026: revenue $180M (+13% year over year), operating margin 29.6%. The chart follows the revenue to costs, profit and cash.

Biocryst Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent guidance

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.